| Literature DB >> 22611493 |
M G Pramateftakis1, D Raptis, D Kanellos, E Christoforidis, G Tsoulfas, I Kanellos, Ch Lazaridis.
Abstract
Aim. The aim of this paper is to investigate if the insertion of the pelvic drainage tube via the perineal wound could be considered as an independent risk factor for perineal healing disorders, after abdominoperineal resection for rectal malignancy. Patients and Methods. The last two decades, 75 patients underwent elective abdominoperineal resection for malignancy. In 42 patients (56%), the pelvic drain catheter was inserted through the perineal wound (PW group), while in the remaining 33 (44%) through a puncture skin wound of the perineum (SW group). Patients' data with respect to age (P = 0.136), stage (P > 0.05), sex (P = 0.188) and comorbidity (P = 0.128) were similar in both groups. 25 patients (PW versus SW: 8 versus 17, P = 0.0026) underwent neoadjuvant radio/chemotherapy. Results. The overall morbidity rate was 36%, but a significant increase was revealed in PW group (52.4% versus 9%, P = 0.0007). In 33.3% of the patients in the PW group, perineal healing was delayed, while in the SW group, no delay was noted. Perineal healing disorders were revealed as the main source of increased morbidity in this group. Conclusion. The insertion of the pelvic drain tube through the perineal wound should be considered as an independent risk factor predisposing to perineal healing disorders.Entities:
Year: 2012 PMID: 22611493 PMCID: PMC3352578 DOI: 10.1155/2012/156935
Source DB: PubMed Journal: Int J Surg Oncol ISSN: 2090-1402
Figure 1Type of a 30-Fr passive drainage system.
Patients treated by APR for a low rectal cancer (n = 75).
| Group | PW ( | SW ( |
| Significance level |
|---|---|---|---|---|
| Age* | 67.2 (22–81) | 71.3 (41–80) | 0.157 | NS |
| Sex ♂/♀ | 26/16 | 21/12 | 0.1878 | NS |
| Tumor loc.** | 3.1 (0.5–4) | |||
| Indication | ||||
| Curative | 38 (90%) | 31 (94%) |
| NS |
| Palliative | 4 (10%) | 2 (6%) |
| NS |
| Neo-adjuvant RT/CT |
|
|
| Sig. |
| Adjuvant RT/CT | 21 | 8 |
| Sig. |
*yrs: value I median (range).
**cm from the dentate line: value is mean (range).
(NS: non-significant; P value >0.05; Sig.: significant, P value <0.05).
Risk factors associated with increased morbidity after APR; comparison of the study groups.
| Group | PW ( | SW ( |
| Significance level |
|---|---|---|---|---|
| Age (>55 yrs) | 29 | 26 | 0.136 | NS |
| Comorbidity | 30 | 27 | 0.128 | NS |
| Diabetes | 11 | 7 | 0.191 | NS |
| Cardiopulmonary dis. | 4 | 5 | 0.212 | NS |
| Vascular dis. | 8 | 9 | 0.153 | NS |
| Obesity (B.M.I. >30 kg/m2) | 12 | 9 | 0.203 | NS |
| Neo-adjuvant RT/CT |
|
|
| Sig. |
NS: non-significant, P value >0.05; Sig.: significant, P value <0.05.
Staging and differentiation.
| Group | PW ( | SW ( |
| Significance level |
|---|---|---|---|---|
| Staging (Duke's) | ||||
| In situ | 2 | — |
| NS |
| A | 3 | 3 |
| NS |
| BI | 6 | 5 |
| NS |
| BII | 14 | 13 |
| NS |
| CI | 3 | 3 |
| NS |
| CII | 11 | 7 |
| NS |
| D | 3 | 2 |
| NS |
| Differentiation | NS | |||
| Well | 10 | 4 |
| NS |
| Moderate | 28 | 23 |
| NS |
| Poor | 4 | 6 |
| NS |
NS: non-significant, P value >0.05.
Complications, morbidity, and mortality.
| Group | PW ( | SW ( |
| Significance level |
|---|---|---|---|---|
| Complications | 22 | 5 |
| Sig. |
| Surgical (specific) | 20 | 3 |
| Sig. |
| Abdominal wound dehiscence | 2 | 2 | ||
| Pelvic abscess* | 1 | — | ||
| Ostomy necrosis** | — | 1 | ||
| Evisceration/reoperation | 1 | — | ||
| Perineal healing disorders |
| — |
| Sig. |
| Delay in perineal healing | 14 | — | ||
| Perineal wound dehiscence | 2 | — | ||
| Medical (nonspecific) | 2 | 2 |
| NS |
| Pneumonia | 1 | — | ||
| Urinary dysfunction | 1 | 1 | ||
| Atrial fibrillation | — | 1 | ||
| Morbidity |
|
|
| Sig. |
| Mortality | 0 | |||
| Overall morbidity |
| |||
*In the presacral space, treated with CT-guided drainage.
**treated with primary relocation.
(NS: non-significant, P value >0.05; Sig.: significant, P value <0.05).
Local recurrence and survival.
| Patients ( | SW | PW | Overall |
| Significance level | |
|---|---|---|---|---|---|---|
| Compl. 5-year follow-up | 26 | 23 | 49 | 0.1336 | NS | |
| Deaths | 7 | 6 | 13 | 0.2831 | NS | |
|
| ||||||
|
|
| |||||
|
| ||||||
| LR** | 1 | 1 | 2 | 12, 24 | ||
| LR** + hepatic metastases | — | 1 | 1 | 6 | ||
| Hepatic metastases | 3 | 2 | 5 | 12, 12, 14, 18,38 | ||
| Brain metastases | 1 | — | 1 | 24 | ||
| Lung + hepatic metastases | 1 | 1 | 2 | 18, 24 | ||
| Hepatic + brain metastases | 1 | — | 1 | 24 | ||
| Stroke | — | 1 | 1 | 36 | ||
|
| ||||||
| Survival (%) | 73.07 | 73.9 |
| 0.253 | NS | |
| Local Recurrence (%) | 3.8 | 8.7 |
| 0.357 | NS | |
*SW versus PW.
**LR: local recurrence.
NS: non-significant, P value >0.05; Sig.: significant, P value <0.05.